Tanshinone I

Tanshinone I is a diterpene quinone compound extracted from Salvia miltiorrhiza that demonstrates potent cytotoxic effects against cancer cells through apoptosis induction. This bioactive compound activates caspase-3 and caspase-7 pathways while providing DNA protection against oxidative damage.

Origin & History

Tanshinone I is a natural diterpenoid quinone primarily extracted from the roots of Salvia miltiorrhiza, also known as Danshen. It can be synthesized chemically, with the first synthesis reported in 1968 using podocarpic acid.

Historical & Cultural Context

Tanshinone I is a significant component of Salvia miltiorrhiza, widely used in traditional Chinese medicine for various conditions. Specific historical uses for Tanshinone I itself are not detailed.

Health Benefits

• Exhibits protective effects against oxidative DNA damage, as observed in preclinical studies. • Demonstrates cytotoxicity against cancer cells, although human trials are lacking. • Potential anti-cancer activity, supported by in-vitro studies. • Induces apoptosis via caspase-3/-7 activation in cell studies. • Structural modifications improve water solubility and bioavailability for potential therapeutic use.

How It Works

Tanshinone I exerts its anti-cancer effects by activating the intrinsic apoptotic pathway, specifically triggering caspase-3 and caspase-7 enzymes that initiate programmed cell death in malignant cells. The compound also functions as an antioxidant by scavenging reactive oxygen species and reducing oxidative DNA damage through direct free radical neutralization. Additionally, it may modulate mitochondrial membrane potential and cytochrome c release to enhance apoptotic signaling cascades.

Scientific Research

No specific human clinical trials or meta-analyses are available for Tanshinone I. Preclinical studies suggest promising biological effects, but these findings are not yet supported by human data.

Clinical Summary

Current evidence for tanshinone I consists primarily of in-vitro and preclinical animal studies, with no published human clinical trials available. Laboratory studies have demonstrated IC50 values ranging from 10-50 μM against various cancer cell lines including hepatocellular carcinoma and breast cancer cells. Preclinical research shows significant DNA damage reduction of 40-60% in oxidative stress models using concentrations of 25-100 μM. The lack of human trials limits the translation of these promising laboratory findings to clinical applications.

Nutritional Profile

Tanshinone I is a pure bioactive compound (abietane-type diterpene quinone) isolated from Salvia miltiorrhiza (Danshen), not a whole food ingredient, and therefore has no conventional macronutrient or micronutrient profile. Molecular formula: C18H12O3, molecular weight: 276.29 g/mol. It is a lipophilic polycyclic aromatic compound with a furan ring fused to a phenanthrenequinone core. As a pure phytochemical, it contains no carbohydrates, proteins, fats, fiber, vitamins, or dietary minerals in the nutritional sense. Bioactive compound concentration: Tanshinone I constitutes approximately 0.01–0.05% by dry weight of Danshen root extract, depending on extraction method. It is one of several tanshinone analogues alongside Tanshinone IIA (the most abundant, ~0.1–0.3% dry weight), cryptotanshinone, and dihydrotanshinone I. Bioavailability: Tanshinone I is highly lipophilic (logP estimated ~3.5–4.0), resulting in poor aqueous solubility (less than 1 µg/mL in water) and limited oral bioavailability in its native form. Structural modifications such as sulfonation, nanoparticle encapsulation, or cyclodextrin complexation have been investigated to improve solubility by up to 100-fold. Absorption is primarily via passive diffusion through lipid membranes; first-pass hepatic metabolism is significant. No established dietary reference intake (DRI) or recommended dose exists, as it is studied exclusively as a pharmacological agent in preclinical models at concentrations typically ranging from 1–20 µM in cell-based assays and 10–50 mg/kg in rodent studies.

Preparation & Dosage

No clinically studied dosage ranges or forms for Tanshinone I are available due to the absence of human clinical data. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Tanshinone IIA, Dihydrotanshinone, Cryptotanshinone, Resveratrol, Curcumin

Safety & Interactions

Safety data for tanshinone I is limited due to the absence of human clinical trials and comprehensive toxicology studies. Potential interactions may occur with anticoagulant medications since related tanshinone compounds can affect platelet aggregation and blood clotting mechanisms. Pregnancy and breastfeeding safety has not been established, and use should be avoided during these periods. High concentrations used in laboratory studies suggest possible cytotoxic effects on healthy cells, though specific dosage thresholds for human safety remain undefined.